Accretion Nutraveda IPO
UpcomingAlready have an account? Apply now
Accretion Nutraveda IPO details
Schedule of Accretion Nutraveda
| Issue open date | 27 Jan 2026 |
| Issue close date | 30 Jan 2026 |
| UPI mandate deadline | 30 Jan 2026 (5 PM) |
| Allotment finalization | 02 Feb 2026 |
| Refund initiation | 03 Feb 2026 |
| Share credit | 03 Feb 2026 |
| Listing date | 04 Feb 2026 |
| Mandate end date | 14 Feb 2026 |
| Lock-in end date for anchor investors (50%) | 04 Mar 2026 |
| Lock-in end date for anchor investors (remaining) | 03 May 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Accretion Nutraveda
Incorporated in 2021 as Accretion Nutraveda Private Limited and converted into a public limited company in 2025, Accretion Nutraveda Limited operates as a healthcare-focused Contract Development and Manufacturing Organization. The company manufactures Ayurvedic and nutraceutical products across multiple dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations. It serves domestic clients and export markets such as Sri Lanka, Singapore, and the USA, combining classical Ayurvedic knowledge with modern nutraceutical science to deliver customized manufacturing solutions.
The company operates from a GMP and WHO-GMP certified leased manufacturing facility in Gujarat, equipped with advanced infrastructure and multiple quality certifications. Its business model is primarily driven by contract manufacturing through domestic sales, merchant exports, and direct exports. Led by an experienced promoter-led board and supported by established customer and supplier relationships, the company has demonstrated strong revenue and profitability growth. Its diversified product portfolio, quality compliance, and focus on long-term partnerships position it well in the growing Ayurvedic and nutraceutical manufacturing space.
Financials of Accretion Nutraveda
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 24.77 |
| Fresh Issue – Proceeds go to the company | 24.77 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Purchase of machineries for automation in existing manufacturing unit | 4.22 (17.04%) |
| Purchase of machineries for new manufacturing setup | 8.03 (32.43%) |
| Working capital requirements | 5.50 (22.21%) |
| General corporate purposes | 7.02 (28.32%) |
Strengths
- Diverse Ayurvedic and nutraceutical dosage capabilities under one facility
- Strong CDMO focus with repeat domestic and export clients
- Multiple quality certifications including WHO-GMP, FSSC 22000 and ISO
- Experienced promoter-led management with hands-on operations control
- Consistent revenue and profitability growth over recent years
Risks
- High revenue dependence on domestic and merchant export segment
- Manufacturing facility is leased, not owned
- Business exposed to regulatory changes in ayurveda and nutraceutical space
- Dependence on a limited number of key customers
- Geographic revenue concentration largely within Gujarat